2026-04-14T02:37:18Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/121842024-11-09T02:41:54Zcom_2072_378070com_2072_378040col_2072_378092

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer Saini, Kamal S. Vidal, Laura Slebe, F. Loibl, Sibylle Quintana, Angela Peg, Vicente Institut Català de la Salut [Quintana A] Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Saini KS] Fortrea, Inc., Durham, USA. Addenbrooke’s Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK. [Vidal L] Fortrea, Inc., Durham, USA. [Peg V] Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament of Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Slebe S] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Oncoclínicas & Co, Jersey City, New Jersey and Sao Paulo, Brazil. [Loibl S] German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany Vall d'Hebron Barcelona Hospital Campus Mama - Càncer - Tractament Mama - Càncer - Immunoteràpia DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica Otros calificadores::Otros calificadores::/uso terapéutico Immune checkpoint inhibitors; Triple-negative breast cancer; Tumor-infiltrating lymphocytes Inhibidors del punt de control immunitari; Càncer de mama triple negatiu; Limfòcits infiltrants de tumors Inhibidores del punto de control inmunitario; Cáncer de mama triple negativo; Linfocitos infiltrantes de tumores Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient's prognosis. 2024-11-06T11:31:50Z 2024-11-06T11:31:50Z 2024-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Quintana A, Saini KS, Vidal L, Peg V, Slebe F, Loibl S, et al. Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer. ESMO Open. 2024 Oct;9(10):103713. 2059-7029 https://hdl.handle.net/11351/12184 10.1016/j.esmoop.2024.103713 39357122 001329647000001 http://hdl.handle.net/11351/12184 eng ESMO Open;9(10) https://doi.org/10.1016/j.esmoop.2024.103713 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Elsevier Scientia